Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Progressive Medical Research

Port Orange, Florida 32127, Egyesült ÁllamokMég nincs intézményhez kötve

39futó vizsgálat
26lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 66 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Alzheimer-kór29 vizsgálat
Elhízás11 vizsgálat
2-es típusú cukorbetegség8 vizsgálat
Zsírmáj (MASLD/MASH)8 vizsgálat
Magas vérnyomás5 vizsgálat
Mild cognitive impairment5 vizsgálat
Osteoarthritis5 vizsgálat
Liver cirrhosis3 vizsgálat
Familiáris hiperkoleszterinémia2 vizsgálat
Koszorúér-betegség2 vizsgálat
Stroke (szélütés)2 vizsgálat
Cushing's syndrome1 vizsgálat
és még 5
Fázis: 3. fázis35 vizsgálat
2. fázis18 vizsgálat
1. fázis7 vizsgálat
1/2. fázis1 vizsgálat
2/3. fázis1 vizsgálat
4. fázis1 vizsgálat
Állapot: Lezárult25 vizsgálat
Toboroz18 vizsgálat
Fut, nem toboroz16 vizsgálat
Még nem toboroz4 vizsgálat
Meghívásos bevonás1 vizsgálat
Felfüggesztve1 vizsgálat
Leállították1 vizsgálat
Fő szponzor: Eli Lilly and Company17 vizsgálat
Amgen3 vizsgálat
Hoffmann-La Roche3 vizsgálat
Mineralys Therapeutics Inc.3 vizsgálat
Alzheon Inc.2 vizsgálat
és még 29

Futó vizsgálatok

Még nem toboroz
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459· 1. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Toboroz
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169· 1. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Toboroz
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361· 2. fázis· Kardigan, Inc.· Forrás
Toboroz
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· 3. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Toboroz
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470· 4. fázis· Alpha Cognition, Inc· Forrás
Contact: Richard Marshall
Toboroz
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· 3. fázis· Amgen· Forrás
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
NCT07223333· 1. fázis· AdipoPharma LLC· Forrás
Contact: (Jackie) Loria Boucher
Toboroz
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
NCT07271186· 2. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138· 2. fázis· Eccogene· Forrás
Contact: Eccogene Clinical Trials
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Alexander White, Site 1612
Toboroz
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484· 2. fázis· Sparrow Pharmaceuticals· Forrás
Contact: Nora Clinical Research Manager
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Bhanu Visvalingam (principal investigator)
Toboroz
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182· 1. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· 3. fázis· Amgen· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Alexander White, Site 1612
Fut, nem toboroz
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
NCT06917404· 3. fázis· Paradigm Biopharmaceuticals Ltd.· Forrás
Toboroz
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400· 1. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Toboroz
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321· 2. fázis· Lighthouse Pharmaceuticals, Inc.· Forrás
Contact: Kyrie Allen
Toboroz
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768· 1. fázis· Eli Lilly and Company· Forrás
Contact: Alexander White (principal investigator)
Fut, nem toboroz
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258· 2. fázis· Eisai Inc.· Forrás
Toboroz
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· GAP Innovations, PBC· Forrás
Contact: Kyrie Allen
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· 2. fázis· Acumen Pharmaceuticals· Forrás
Meghívásos bevonás
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031· Cognito Therapeutics, Inc.· Forrás
Fut, nem toboroz
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Fut, nem toboroz
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain
NCT04809376· 2/3. fázis· Paradigm Biopharmaceuticals USA (INC)· Forrás
Fut, nem toboroz
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339· 3. fázis· Applied Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
NCT07016412· 2. fázis· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Forrás
Lezárult
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
NCT06864104· 2. fázis· Kardigan, Inc.· Forrás
Lezárult
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
NCT06675929· 2. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935· 2. fázis· Carmot Therapeutics, Inc.· Forrás
Leállították
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883· 3. fázis· Alzheon Inc.· Forrás
Lezárult
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597· 3. fázis· NewAmsterdam Pharma· Forrás
Lezárult
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
NCT05769608· 2. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
NCT05669599· 2. fázis· Amgen· Forrás
Lezárult
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
NCT05762471· 1/2. fázis· Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics· Forrás
Lezárult
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
NCT05637801· Cognito Therapeutics, Inc.· Forrás
Lezárult
Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee
NCT05449132· 3. fázis· Grünenthal GmbH· Forrás
Lezárult
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
NCT05377489· 3. fázis· Grünenthal GmbH· Forrás
Lezárult
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722· 3. fázis· NewAmsterdam Pharma· Forrás
Lezárult
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
NCT04880031· 2. fázis· GlaxoSmithKline· Forrás
Lezárult
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· 2. fázis· Gilead Sciences· Forrás
Lezárult
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
NCT04770220· 3. fázis· Alzheon Inc.· Forrás
Lezárult
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
NCT04592874· 2. fázis· Alector Inc.· Forrás
Lezárult
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
NCT04640077· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
NCT04451408· 1. fázis· Eli Lilly and Company· Forrás
Lezárult
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· 3. fázis· Novartis Pharmaceuticals· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 15.

Építés alatt, nem éles – Progressive Medical Research: vizsgálati helyszín – Frontlight Research